Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 ...

Hopefully, by now, you're all familiar with the grow, expand, build framework that we have adopted to define our strategy to sustain near- and long-term growth for both ZORYVE and the company overall.

The best at-home, FDA-approved red light therapy tools and panels for the face and body in 2026, according to editors, ...

In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while ...

These days, though, consumers are looking for a high-end, sensorial experience from their hair care. And with the economy in ...

If your skin still appears dry and lackluster despite using expensive skincare products, you might be missing out on your ...

Your nails grow about three millimeters per month, and in all that slow, steady progress they’re quietly recording a running ...

For Maryland residents dealing with seasonal allergies, which is basically everyone who ventures outside between March and ...

Use of IL-17 inhibitors is effective and safe for the treatment of PsO involving difficult-to-treat anatomical sites.

The National Psoriasis Foundation has issued a statement that endorses consideration of adjunctive GLP-1 receptor agonists in ...

Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment for plaque psoriasis. The US regulator has approved icotrokinra under the ...

Bimekizumab is associated with significant complete clearance rates at 4 years among patients with scalp, nail, or palmoplantar psoriasis.